Useful pharmacodynamic endpoints in children: selection, measurement, and next steps

Area of Science:

• Pediatric clinical pharmacology
• Biomarkers and drug response assessment
• Clinical trial methodology in pediatrics

Background:

• Pharmacodynamic (PD) endpoints are critical for evaluating the benefit-to-risk ratio of pediatric therapeutics.
• Current pediatric clinical research often lacks standardized approaches to selecting and measuring PD endpoints.
• Ensuring therapeutic efficacy and safety in children necessitates robust PD endpoint evaluation.

Purpose of the Study:

• To discuss the selection of appropriate pharmacodynamic (PD) endpoints for pediatric efficacy and safety studies.
• To review existing guidance and identify key considerations for PD endpoint selection in pediatric clinical trials.
• To propose criteria for useful PD endpoint selection and measurement in pediatric populations.

Main Methods:

• Overview of existing guidance on PD endpoint selection in pediatric clinical research.
• Identification of relevant considerations: biomarkers, modeling, compliance, scoring systems, and validated tools.
• Proposal of a minimal set of criteria for useful PD endpoint selection and measurement.

Main Results:

• Useful PD endpoints in children must be clinically relevant, responsive to treatment/disease, reproducible, and reliable.
• Significant validation efforts are often required for PD endpoints across pediatric disease areas.
• Current heterogeneity in PD endpoint definitions and measurements necessitates improvement.

Conclusions:

• There is an urgent need for internationally agreed, validated, and condition-specific pediatric PD endpoints.
• Standardization is essential to address the heterogeneity in current pediatric PD endpoint definitions and measurements.
• Consideration of all stakeholders, including patients and families, is vital for developing effective PD endpoints.